Product for preventing and/or treating diabetes

Abstract

The invention discloses a product for preventing and / or treating diabetes. The product comprises berberine, salvianolic acid B, ginseng total saponin and emodin, wherein the mass ratio of berberine to salvianolic acid B to ginseng total saponin to emodin is (50-150):(60-120) :(1-3) :(1-3). The medicament (TP) for treating diabetes is Chinese herb extract and has the advantages of definite ingredients, little toxic or side effect, simple treatment process, obvious curative effect and wide application prospect.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a product for preventing and / or treating diabetes. Background technique [0002] Diabetes is caused by the interaction of genetic and environmental factors. It is a progressive disease characterized by relative or absolute lack of insulin. Type 2 accounts for the vast majority. With the improvement of living standards, obesity and population aging, its incidence rate increases rapidly. High, according to the statistics of the International Diabetes Federation (IDF), there are currently 233 million diabetics in the world, and by 2025, 380 million people worldwide will suffer from diabetes. [0003] At present, the fastest growing countries in the world are China, India and other developing countries. At present, there are at least 26 million diabetic patients in my country, and the prevalence rate of diabetes in big cities is as high as about 8%. A common threat to survival is on...

AI Technical Summary

Problems solved by technology

[0004] Insulin resistance (IR) and β-cell dysfunction are two interrelated defects of type 2 diabetes: increased insulin secretion can compensate Insulin resistance, and the corresponding increase in insulin sensitivity can supplement the lack of insulin secretion to a certain extent; insulin resistance runs through the whole process of type 2 diabetes, and if the pancreatic β-cell function can effectively compensate after insulin resistance, normal glucose tolerance can be maintained ; The compensatory ability of impaired glucose tolerance is slightly reduced; in the early stage of diabetes, the β-cell function still has a certain secretory function, but it is obviously insufficient for high blood sugar; in the middle and late stage of diabetes, the β-cell function further decreases and fails

However, there is no drug that directly targets the protection of islet β-cell function

Images